Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Tillmanns

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Gynecologic Oncology|December 3, 2005
Preoperative predictors of positive margins after loop electrosurgical excisional procedure-ConeTodd D Tillmanns, Camille A Falkner, David B Engle, et al.
Gynecologic Oncology|August 7, 2004
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?Scott A Kamelle, Teresa L Rutledge, Todd D Tillmanns, et al.
Gynecologic Oncology|September 24, 2004
A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?Teresa L Rutledge, Scott A Kamelle, Todd D Tillmanns, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
Cervical cancer guidelines. Clinical practice guidelines in oncologyNelson Teng, Nadeem R Abu-Rustum, Afshin Bahador, et al.
Future Oncology (London, England)|April 7, 2026
Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancerShannon N Westin, Kathleen Moore, Hye Sook Chon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2023
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E TrialShannon N Westin, Kathleen Moore, Hye Sook Chon, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Gynecologic Oncology|December 3, 2005
Preoperative predictors of positive margins after loop electrosurgical excisional procedure-ConeTodd D Tillmanns, Camille A Falkner, David B Engle, et al.
Gynecologic Oncology|August 7, 2004
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?Scott A Kamelle, Teresa L Rutledge, Todd D Tillmanns, et al.
Gynecologic Oncology|September 24, 2004
A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?Teresa L Rutledge, Scott A Kamelle, Todd D Tillmanns, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
Cervical cancer guidelines. Clinical practice guidelines in oncologyNelson Teng, Nadeem R Abu-Rustum, Afshin Bahador, et al.
Future Oncology (London, England)|April 7, 2026
Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancerShannon N Westin, Kathleen Moore, Hye Sook Chon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2023
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E TrialShannon N Westin, Kathleen Moore, Hye Sook Chon, et al.
Pageof 3